We analyzed the effects of imatinib mesylate and dasatinib on two CML-derived cell lines (JURL-MK1 and MOLM-7), and two cell lines not expressing BCR-ABL protein (HEL and JURKAT). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.